

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ/ JPW/GJG/DJK		Serial No. Not yet known	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Moses Rodriguez and Daren Ure			
					Filing Date herewith		Group Art Unit 1649	


U.S. PATENT DOCUMENTS														
Examiner Initial	Exhibit No.	Document Number								Date	Name	Class	Subclass	Filing Date if Appropriate
CyW		5	5	9	1	6	2	9	1/7/1997	Rodriguez, et al.				
		5	8	0	0	8	0	8	9/1/1998	Konfino, et al.				
		5	9	8	1	5	8	9	11/9/1999	Konfino, et al.				
		6	0	4	8	8	9	8	4/11/2000	Konfino, et al.				
		6	0	5	4	4	3	0	4/25/2000	Konfino, et al.				
CyW	1	20	02	01	82	2	1	0	12/5/2002	Rodriguez, et al.				

FOREIGN PATENT DOCUMENTS																
		Document Number								Date	Country	Class	Subclass	Translation		
		Yes	No													
CyW		WO	00	0	5	2	5	0	2/3/2000							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
CyW	2	Allowed claims of U.S. Serial No. 09/885,227 (Rodriguez, et al.), U.S. Patent Publication No. 20020182210 A1, for the Examiner's convenience.
		Ben-Nun, A. et al. 1996. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of Copolymer 1 on MOG-induced disease. J. Neurol. 243(Suppl 1): S14-S22.
		Fridkis-Hareli, et al., "Direct Binding of Myelin Basic Protein and Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells - Specificity and Promiscuity", Proc. Natl. Acad. Sci. USA, 1994, 91: 4872-4876.
CyW		Lisak, R.P. et al. 1983. Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of Experimental Allergic Encephalomyelitis (EAE). J. Neurol. Sci. 62: 281-293.

EXAMINER <i>Choy</i>	DATE CONSIDERED 01/20/06
----------------------	-----------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AA/ JPW/ GJG/DJK		Serial No. Not yet known				
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants: Moses Rodriguez and Daren Ure						
					Filing Date herewith		Group Art Unit 1649				
U.S. PATENT DOCUMENTS											
Examiner Initial	Exhibit No.	Document Number				Date	Name	Class			
FOREIGN PATENT DOCUMENTS											
		Document Number				Date	Country	Class	Subclass	Translation	
										Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
Cyl		Pavelko, K.D., B.G. van Engelen and M. Rodriguez. 1998. Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination. J. Neurosci. 18: 2498-2505.									
		Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158: 2471-2476.									
		Sela, M. et al. 1990. Suppressive activity of Cop-I in EAE and its relevance to multiple sclerosis. Bull. Inst. Pasteur. 88:303-314.									
		Teitelbaum, D., A. Meshorer, T. Hirshfeld, R. Arnon and M. Sela. 1971. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1: 242-248.									
		Teitelbaum, D., C. Webb, A. Meshorer, R. Arnon and M. Sela. 1973. Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur. J. Immunol. 3: 273-279.									
		Teitelbaum, D. et al. 1996. Copolymer I inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64: 209-217.									
		Teitelbaum, D., R. Aharoni, M. Sela and R. Arnon. 1991. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic Copolymer 1. Proc. Natl. Acad. Sci. USA 88:9528-9532.									
Cyl		Webb, C. et al. 1973. In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing Experimental Allergic Encephalomyelitis, Eur. J. Immunol. 3: 279-286.									
EXAMINER 					DATE CONSIDERED 1/20/06						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											



Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442
---	------------------------------	-------------------------------

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicant:
Moses Rodriguez and Daren Ure

Filing Date:
February 10, 2004

Group Art Unit
1614-1649

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
CyW	US 3 8 4 9 5 5 0	11/19/74	Teitelbaum et al.			
CyW	US 3 9 9 1 2 1 0	11/09/76	Shea			
CyW	US 4 3 3 9 4 3 1	7/13/82	Gaffer			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No
CyW WO 8 8 1 0 1 2 0	12/29/88	PCT				
CyW WO 9 2 0 2 5 4 3	2/20/92	PCT				
CyW WO 9 4 0 3 4 8 4	2/17/94	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


CyW	Abramsky, et al., "Effect of a Synthetic Polypeptide (COP-1) on Patients with Multiple Sclerosis and with Acute Disseminated Encephalomyelitis", <u>J. Neurol. Sci.</u> , 1977, 31, 433-438;
	Aharoni, et al., "T Suppressor Hybridomas and Interleukin-2-Dependent Lines Induced by Copolymer 1 or by Spinal Cord Homogenate Down-Regulate Experimental Allergic Encephalomyelitis", <u>Eur. J. Immunol.</u> , 1993, 23, 17-25;
	Aharoni, et al., "Studies on the Mechanism and Specificity of the Effect of the Synthetic Random Copolymer GLAT on Graft-versus-Host Disease", <u>Immunol. Letters</u> , 1997, 58, 79-87;
	Alvord, et al., "Myelin Basic Protein Treatment of Experimental Allergic Encephalomyelitis in Monkeys", <u>Ann. Neurol.</u> , 1979, 6, 469-473;
	Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Copolymer Immunological Cross Reactive with Basic Encephalitogen", <u>Israel J. Med. Sci.</u> , 1972, 8, 1759-17
	Arnon, et al., "Suppression of EAE in Baboons by a Synthetic Polymer of Amino Acids", <u>Neurol.</u> , 1978, 28, 336 (Abstract);
	Arnon, "A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy" in <u>Progress in Multiple Sclerosis Research</u> (Bauer, Ritter, eds., Springer Verlag New York, 1980) 416-418;
	Arnon, et al., "Desensitization of Experimental Allergic Encephalomyelitis with Synthetic Peptide Analogues" in <u>The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis</u> (Academic Press, New York, 1980) 105-107;
	Arnon, "Experimental Allergic Encephalomyelitis - Susceptibility and Suppression", <u>Immunological Rev.</u> , 1981, 55, 5-30;
CyW	Arnon, et al., "Suppression of Demyelinating Diseases by Synthetic Copolymers", in <u>A Multidisciplinary Approach to Myelin Disease</u> (G. Serlupi Crescenzi, ed., Plenum Publishing Corp., 1988) 243-250;

EXAMINER Chang-Yu Song DATE CONSIDERED 1/20/06

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant: Moses Rodriguez and Daren Ure			
				Filing Date: February 10, 2004		Group Art Unit 1614 1649	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number		Date	Name	Class	Subclass
CyW		US 5 2 0 4 0 9 9	4/20/93	Barbier et al.			
CyW		US 5 5 5 4 3 7 2	9/10/96	Hunter et al.			
CyW		US 5 5 8 3 0 3 1	12/10/96	Stern			
FOREIGN PATENT DOCUMENTS							
		Document Number		Date	Country	Class	Subclass
							Translation
							Yes No
CyW		WO 9 4 2 6 7 7 4	11/24/94	PCT			
CyW		WO 9 5 3 1 9 9 7	11/30/95	PCT			
CyW		WO 9 5 3 3 4 7 5	12/14/95	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
CyW		Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by Cop-1 - Relevance to Multiple Sclerosis", <u>Israel J. Med. Sci.</u> , 1989, 25, 686-689;					
		Arnon, et al., "On the Existence of Suppressor Cells", <u>Int. Arch. Allergy Immunol.</u> , 1993, 100, 2-7;					
		Arnon, et al., "Immunomodulation of Experimental Allergic Encephalomyelitis", <u>Israel J. Med. Sci.</u> , 1993, 29, 175-181;					
		Arnon, et al., "Immunospecific Drug Design - Prospects for Treatment of Autoimmune Disease", <u>Therapeutic Immunol.</u> , 1994, 1, 65-70;					
		Asakura and Rodriguez, "A Unique Population of Circulating Autoantibodies Promotes Central Nervous System Remyelination", <u>Multiple Sclerosis</u> , 1998, 4, 217-221;					
		Asakura, et al., "Targeting of IgMk Antibodies to Oligodendrocytes Promotes CNS Remyelination", <u>J. Neurosci.</u> , 1998, 18(19): 7700-7708;					
		Babu, et al., "Reevaluation of Response Patterns of Nonresponder Mice to GIPhe Polymers", <u>Immunogen.</u> , 1983, 18(1): 97-100 (Abstract);					
		Babu, et al., "Ir Gene Control of T and B Cell Responses to Determinants in (Glu Lys Ala) Terpolymer", <u>J. Immunogenet.</u> , 1984, 11(3-4): 251-254;					
		Bansil, et al., "Multiple Sclerosis: Pathogenesis and Treatment", <u>Seminars in Neurol.</u> , June 1994, 14(2), 146-153;					
		Baumhefner, et al., "Copolymer 1 as Therapy for Multiple Sclerosis: The Cons", <u>Neurol.</u> , 1988, 38(Suppl. 2), 69-71;					
		Baxevanis, et al., "Genetic Control of T-Cell Proliferative Responses to Poly (Glu ⁴⁰ Ala ⁶⁰) and Poly (Glu ⁵¹ Lys ³⁴ Tyr ¹⁵): Subregion-Specific Inhibition of the Responses with Monoclonal Ia Antibodies", <u>Immunogenetics</u> , 1980, 11: 617-628;					
CyW		Bieber, et al., "Antibody-Mediated Remyelination: Relevance to Multiple Sclerosis", <u>Multiple Sclerosis</u> , 2000, 6: S1-S5;					
EXAMINER		Chang		DATE CONSIDERED 1/20/06			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure		
					Filing Date: February 10, 2004	Group Art Unit 1614 1649	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
CyW	US	5 6 2 3 0 5 2	04/22/97	McLean et al			
CyW	US	5 6 2 7 2 0 6	05/06/97	Hupe et al			
CyW	US	5 6 6 8 1 1 7	09/16/97	Shapiro			
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
CyW	WO	9 5 2 6 9 8 0	10/12/95	PCT			
CyW	WO	9 5 3 1 9 9 0	11/30/95	PCT			
CyW	WO	9 8 3 0 2 2 7	07/16/98	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
CyW		Bieber, et al., "Humoral Autoimmunity as a Mediator of CNS Repair", <u>Trends in Neurosci.</u> , 2001, 24(11): S39-S44;					
		Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", <u>Ann. Neurol.</u> , 1980, 8, 117 (Abstract);					
		Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", <u>Trans. Am. Neurol. Assoc.</u> , 1980, 105, 348-350;					
		Bornstein, et al., "Multiple Sclerosis: Trial of a Synthetic Polypeptide", <u>Ann. Neurol.</u> , 1982, 11, 317-319;					
		Bornstein, et al., "Clinical Trials of Copolymer 1 in Multiple Sclerosis", <u>Ann. N.Y. Acad. Sci. (USA)</u> , 1984, 366-372;					
		Bornstein, et al., "Clinical Trials of a Synthetic Polypeptide (Copolymer 1) for the Treatment of Multiple Sclerosis" in Gonsett et al., <u>Immunological and Clinical Aspects of Multiple Sclerosis</u> (MTP Press, The Hague, 1984) 144-150;					
		Bornstein, et al., "Multiple Sclerosis: Clinical Trials of a Synthetic Polypeptide, Copolymer 1", <u>Neurol.</u> , 1985, 35 (Suppl. 1), 103 (Abstract);					
		Bornstein, "Cop 1 May be Beneficial for Patients with Exacerbating-remitting Form of Multiple Sclerosis", <u>Adv. Ther. (USA)</u> , 1987, 4, 206 (Abstract);					
		Bornstein, et al., "A Pilot Trial of Cop 1 in Exacerbating-remitting Multiple Sclerosis", <u>New Eng. J. Med.</u> , 1987, 317(7), 408-414;					
		Bornstein, et al., "Clinical Experience with COP-1 in Multiple Sclerosis", <u>Neurol.</u> , 1988, 38(Suppl. 2), 66-69;					
CyW		Bornstein, et al., "Pilot Trial of COP-1 in Chronic Progressive Multiple Sclerosis: Preliminary Report", from <u>The International Multiple Sclerosis Conference: An Update on Multiple Sclerosis</u> , Roma (Italy), September 15-17, 1988, in <u>Elsevier Science Publisher</u> , 1989, 225-232;					
EXAMINER		DATE CONSIDERED					
Chang-Yu Jung		1/20/06					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442						
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure								
					Filing Date: February 10, 2004		Group Art Unit 1614 1649						
U.S. PATENT DOCUMENTS													
Examiner Initial		Document Number				Date	Name	Class	Subclass	Filing Date if Appropriate			
CyW	US	5	7	1	9	2	6	9	02/17/98	Acton, III et al.			
CyW	US	5	7	3	4	0	2	3	03/31/98	Bishwajit et al.			
CyW	US	5	8	5	8	9	6	4	01/12/99	Aharoni, et al.			
FOREIGN PATENT DOCUMENTS													
		Document Number				Date	Country	Class	Subclass	Translation			
										Yes	No		
CyW	WO	0	0	0	5	2	4	9	02/03/00	PCT			
CyW	WO	0	0	1	8	7	9	4	04/06/00	PCT			
CyW	WO	0	0	2	0	0	1	0	04/13/00	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
CyW		Bornstein, et al., "A Pilot Trial of Cop 1 in Exacerbating-remitting Multiple Sclerosis", <u>New Eng. J. Med.</u> , 1987, 317(7), 408-414;											
		Bornstein, et al., "Clinical Experience with COP-1 in Multiple Sclerosis", <u>Neurol.</u> , 1988, 38(Suppl. 2), 66-69;											
		Bornstein, et al., "Pilot Trial of COP-1 in Chronic Progressive Multiple Sclerosis: Preliminary Report", from <u>The International Multiple Sclerosis Conference: An Update on Multiple Sclerosis</u> , Roma (Italy), September 15-17, 1988, in <u>Elsevier Science Publisher</u> , 1989, 225-232;											
		Bornstein, et al., "Clinical Trials of Cop 1 in Multiple Sclerosis" in <u>Handbook of Multiple Sclerosis</u> (S.D. Cook Marcel Rekker, ed., 1990) 469-480;											
		Bornstein, et al., "A Placebo-controlled, Double-blind, Randomized Two-center, Pilot Trial of Cop 1 in Chronic Progressive Multiple Sclerosis", <u>Neurol.</u> , 1991, 41, 533-539;											
		Bornstein, et al., "Treatment of Multiple Sclerosis with Copolymer 1" in <u>Treatment of Multiple Sclerosis: Trial Design, Results and Future Perspectives</u> (Rudick R.A. & Goodkin D.E., eds., Springer Verlag, London, 1992) 173-198;											
		Brosnan, et al., "The Response of Normal Human Lymphocytes to Copolymer 1", <u>J. Neuropath. Exp. Neurol.</u> , 1983, 42, 356 (Abstract);											
		Brosnan, et al., "Copolymer 1: Effect on Normal Human Lymphocytes", <u>Ann. N.Y. Acad. Sci. (USA)</u> , 1984, 436, 498-499;											
		Brosnan, et al., "Immunogenic Potentials of Copolymer 1 in Normal Human Lymphocytes", <u>Neurol.</u> , 1985, 35, 1754-1759;											
CyW		Burns, et al., "Human Cellular Immune Response in Vitro to Copolymer 1 and Myelin Basic Protein (MBP)", <u>Neurol.</u> , 1985, 35 (Suppl. 1), 170 (Abstract);											
EXAMINER						DATE CONSIDERED							
						1/20/06							
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>													

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10776,442	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure			
					Filing Date: February 10, 2004		Group Art Unit 1614-1649	
U.S. PATENT DOCUMENTS								
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate		
CyW	US 5 8 8 6 1 5 6	03/23/99	McLean et al.					
CyW	US 5 9 5 8 9 7 2	09/28/99	Hupe, et al.					
CyW	US 6 2 1 4 7 9 1	04/10/01	Arnon, et al.					
FOREIGN PATENT DOCUMENTS								
	Document Number	Date	Country	Class	Subclass	Translation		
						Yes	No	
CyW	WO 0 0 2 7 4 1 7	05/18/00	PCT					
CyW	WO 0 1 8 5 7 9 7	11/15/01	PCT					
CyW	WO 0 1 5 2 8 7 8	07/26/01	PCT					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
CyW	Burns, et al., "Human Cellular Immune Response to Copolymer 1 and Myelin Basic Protein", <u>Neurol.</u> , 1986, <u>36</u> , 92-94;							
	Burns, et al., "Failure of Copolymer 1 to Inhibit the Human T-cell Response to Myelin Basic Protein", <u>Neurol.</u> , 1991, <u>41</u> , 1317-1319;							
	Carter, et al., "Newer Drug Therapies for Multiple Sclerosis", <u>Drug Therapy</u> , 1990, 31-32, 37-39, 42-43;							
	Clinical Trial Protocol No. 9001, Teva Pharmaceutical Industries, Ltd., first patient enrolled October 23, 1991;							
	Clinical Trial Protocol No. 9002, Lemmon Co. and Teva Pharmaceutical Industries, Ltd., first patient enrolled June 17, 1993;							
	Cohen, "Fundamental Immunology", <u>Systemic Autoimmunity</u> , 4 th Ed., 1999, 1083;							
	Cotton, "Options for Multiple Sclerosis Therapy", <u>J.A.M.A. Medical News & Perspectives</u> , 1994, <u>272</u> (18), 1393;							
	De Kruffy, et al., "Analysis of T Cell Responses to Poly-L (GluLys) at the Clonal Level. I. Presence of Responsive Clones in Nonresponder Mice", <u>Eur. J. Immunol.</u> , 1987, 17 (8): 1115-1120 (Abstract);							
	Deeb, et al., "Comparision of Freund's and Ribi Adjuvants for Inducing Antibodies to the Synthetic Antigen (TG)-AL in Rabbits", <u>J. Immunol. Methods</u> , 1992, 152(1): 105-113 (Abstract);							
	Dorling, et al., "Prospects for Xenografting", <u>Curr. Opinions Immunol.</u> , 1994, <u>6</u> , 765-769;							
	Durelli, "Immunotherapeutics of Multiple Sclerosis", <u>Istituto di Clinica delle Malattie del Sistema Nervoso Universita di Torino</u> , 467-475;							
CyW	Falo et al., "Analysis of Antigen Presentation by Metabolically Inactive Accessory Cells and Their Isolated Membranes", <u>Proc. Natl. Acad. Sci. USA</u> , 1985, 82(19): 6647-6651 (Abstract);							
EXAMINER		DATE CONSIDERED						
Changshu Wang		1/20/06						
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442						
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure								
					Filing Date: February 10, 2004		Group Art Unit 1614-1649						
U.S. PATENT DOCUMENTS													
Examiner Initial	US	Document Number						Date	Name	Class	Subclass	Filing Date if Appropriate	
CyW	US	6	3	4	2	4	7	6	01/29/02	Konfino et al.			
CyW	US	6	3	6	2	1	6	1	03/26/02	Konfino et al.			
CyW	US-2001	00	5	5	5	6	8	A1	12/27/01	Gilbert et al.			
FOREIGN PATENT DOCUMENTS													
		Document Number						Date	Country	Class	Subclass	Translation Yes No	
CyW	WO	0	1	9	3	8	9	3	12/13/01	PCT			
CyW	WO	0	1	6	0	3	9	2	08/23/01	PCT			
CyW	WO	0	1	9	3	8	2	8	12/13/01	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
CyW		Ferrara, et al., "Graft-Versus-Host Disease", <u>New Eng. J. Med.</u> , 1991, 324, 667-674;											
		Francis, "The Current Therapy of Multiple Sclerosis", <u>J. Clin. Pharmacy and Therapeutics</u> , 1993, 18, 77-84;											
		Fridkis-Hareli, et al., "Copolymer 1 Displaces MBP, PLP and MOG, but Can Not be Displaced by these Antigens from the MHC Class II Binding Site", <u>Department of Chemical Immunology, The Weizmann Institute of Science</u> , 1994;											
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein do not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", <u>Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel</u> , 1994;											
		Fridkis-Hareli, et al., "Specific and Promiscuous Binding of Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", <u>Israeli Biochem. Soc.</u> , 1994, 21-22 (Abstract);											
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Undergo Processing Prior to the Binding to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells", <u>Israeli Immunol. Soc.</u> , May 3-4, 1994 (Abstract);											
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen-Presenting Cells", <u>J. Neurochem.</u> , 1994, 63(Suppl. I), 561;											
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells" in <u>Neurochem Mtg.</u> , August 14-19, 1994;											
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells", <u>Cell. Immunol.</u> , 1995, 163, 229-236;											
CyW		Fridkis-Hareli, et al., "Promiscuous Binding of Synthetic Copolymer 1 to Purified HLA-DR Molecules", <u>J. Immunol.</u> , 1998, 160, 4386-4397;											
EXAMINER		<div style="display: flex; justify-content: space-between;"> <i>Cheng-Yu Wang</i> DATE CONSIDERED 12/0/06 </div>											
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>													

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure			
					Filing Date: February 10, 2004		Group Art Unit 1614-1649	
U.S. PATENT DOCUMENTS								
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate		
CYW	US-2002 00 3 7 8 4 8 A1	03/28/02	Eisenbach-Schwartz et al.					
CYW	US-2002 00 3 7 8 4 8 A1	03/28/02	Eisenbach-Schwartz et al.					
CYW	US-2003 00 0 4 0 9 9 A1	01/02.03	Eisenbach-Schwartz et al.					
FOREIGN PATENT DOCUMENTS								
	Document Number	Date	Country	Class	Subclass	Translation		
						Yes	No	
CYW	WO 0 1 9 7 8 4 6	12/27/01	PCT					
CYW	EP 0 3 5 9 7 8 3	08/22/90	Europe					
CYW	EP 0 3 8 3 6 2 0	11/29/95	Europe					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
CYW	Fridkis-Hareli, et al., "Synthetic Amino Acid Copolymers that Bind to HLA-DR Proteins and Inhibit Type II Collagen-reactive T Cell Clones", <u>Proc. Natl. Acad. Sci.</u> , October 1998, <u>95</u> , 12528-12531;							
	Fridkis-Hareli, et al., "Binding of Random Copolymers of Three Amino Acids to Class II MHC Molecules", <u>Intl. Immunol.</u> , 1999, <u>11</u> (5): 635-641;							
	Fridkis-Hareli, et al., "Synthetic Peptides that Inhibit Binding of the Collagen Type II 261-273 Epitope to Rheumatoid Arthritis-Associated HLA-DR1 and DR4 Molecules and Collagen-Specific T-cell Responses", Database HCAPLUS on STN, Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark, HCAPLUS AN: 2000:455053, Human Immunology, 2000, <u>61</u> (7), 640-650 (Abstract);							
	Grgacic, et al., "Cell-mediated Immune Response to Copolymer 1 in Multiple Sclerosis Measured by the Macrophage Procoagulant Activity Assay", <u>Int. Immunol.</u> , 1990, <u>2</u> (8), 713-718;							
	Harrison and Hafler, "Antigen-Specific Therapy for Autoimmune Disease", <u>Current Opin. Immunol.</u> , 2000, <u>12</u> (6): 704-711;							
	Henry, Celia M., "Special Delivery", <u>Chem. and Eng. News</u> , Sept. 18, 2000, 49-54;							
	Herzenberger, et al., "Lack of Immune Response Gene Control for Induction of Epitope-specific Suppression by TGAL Antigen", <u>Nature</u> , 1982, 295: 329-331 (Abstract);							
	Jacobs, et al., "Advances in Specific Therapy for Multiple Sclerosis", <u>Neurol.</u> , 1994, <u>7</u> , 250-254;							
	Johnson, "Clinical Studies in Copolymer 1 Therapy for Exacerbating-relapsing Multiple Sclerosis", in <u>Congress for Advances in the Understanding and Treatment of Multiple Sclerosis</u> , Boston (USA), Oct. 28-29, 1992;							
CYW	Johnson, "Experimental Therapy of Relapsing-Relapsing Multiple Sclerosis with Copolymer-1", <u>Ann. Neurol.</u> , 1994, <u>36</u> (Suppl.), 115-117;							
EXAMINER		DATE CONSIDERED						
Chang-Yu Wang		1/20/06						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442						
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure								
					Filing Date: February 10, 2004		Group Art Unit 1614 1649						
U.S. PATENT DOCUMENTS													
Examiner Initial	Country	Document Number						Date	Name	Class	Subclass	Filing Date if Appropriate	
CYW	US	09	3	5	9	0	9	9	07/12/99	Strominger et al.			
CYW	US	09	4	0	5	7	4	3	09/24/99	Gad et al.			
CYW	US	09	4	8	7	7	9	3	01/20/00	Eisenbach-Schwartz, et al.			
FOREIGN PATENT DOCUMENTS													
		Document Number						Date	Country	Class	Subclass	Translation	
												Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
CYW		Johnson, Management of Relapsing/Remitting Multiple Sclerosis with Copolymer 1 (Copaxone)", <u>Chemical Abstracts</u> , 1996, <u>125</u> , 291993b;											
		Ju, et al., "Idiotypic Analysis of Antibodies Against the Terpolymer L-glutamic Acid 60-L-alanine30-L-tyrosine10 (GAT). IV. Induction of CGAT Idiotypic Following Immunization with Various Synthetic Polymers Containing Glutamic Acid and Tyrosine", <u>Eur. J. Immunol.</u> , 1979, 9(7): 553-560 (Abstract);											
		Kay, et al., "The Mechanism of Action of FK 506", <u>Transplantation Proceedings</u> , 1990, 22(1, Suppl. 1), 96-99;											
		Keith, et al., "The Effect of COP 1, a Synthetic Polypeptide, on Chronic Relapsing Experimental Allergic Encephalomyelitis in Guinea Pigs" <u>J. Neurol. Sci.</u> , 1979, 42, 267-274;											
		Keleman, et al., "Graft-versus-Host Disease in Bone Marrow Transplantation: Experimental, Laboratory, and Clinical Contributions of the Last Few Years", <u>Int. Arch. Allergy Immunol.</u> , 1993, 102, 309-320;											
		Kepsutlu, et al., "Evaluation of Chitosan Used as an Excipient in Tablet Formulations", Database HCAPLUS on STN, Department of Pharmaceutical Technology, Gulhane Military Medical Academy, Ankara, 06018, Turkey, HCAPLUS AN: 1999: 590411, Acta. Pol. Pharm. 1999, 56(3), 227-235 (Abstract);											
		Kott, et al., "COP-1 Increases Suppressor Cells Number in Multiple Sclerosis", <u>Israel Neurological Assoc.</u> , December 19-20, 1994, Herzliya (Israel), 17;											
		Kropshofer, et al., "Self-Peptides from Four HLA-DR Alleles Share Hydrophobic Anchor Residues Near the NH ₂ -Terminal Including Proline as a Stop Signal for Trimming", <u>J. Immunol.</u> , 1993, 151: 4732-4742;											
		Lai, et al., "Complementation of Class II a Alleles in the Immune Response to (Glulystyr) Polymers", <u>Exp. Clin. Immunogenet.</u> , 1986, 3(1): 38-48 (Abstract);											
CYW		Lai, et al., "Monoclonal T Cell Responses to Two Epitopes on a Single Immunogen Controlled by Two Distinct Genes", <u>J. Immunol.</u> , 1986, 136(10): 3799-3804 (Abstract);											
EXAMINER		Chang-Yu Song						DATE CONSIDERED					1/20/06
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>													

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442						
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure								
					Filing Date: February 10, 2004		Group Art Unit 1614-1649						
U.S. PATENT DOCUMENTS													
Examiner Initial	US	Document Number						Date	Name	Class	Subclass	Filing Date if Appropriate	
CyW	US	09	6	2	0	2	1	6	07/20/00	Eisenbach-Schwartz, et al.			
CyW	US	09	7	6	5	3	0	1	01/22/01	Eisenbach-Schwartz, et al.			
CyW	US	09	7	6	5	6	4	4	1/22/01	Eisenbach-Schwartz, et al.			
FOREIGN PATENT DOCUMENTS													
		Document Number						Date	Country	Class	Subclass	Translation	
												Yes No	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
CyW		Lando, et al., "Experimental Allergic Encephalomyelitis in Mice - Suppression and Prevention with COP-1", <u>Israel J. Med. Sci.</u> , 1979, 15, 868-869 (Abstract);											
		Lando, et al., "Effect of Cyclophosphamide on Suppressor Cell Activity in Mice Unresponsive to EAE", <u>J. Immunol.</u> , 1979, 123, 2156-2160 (Abstract);											
		Lee, et al., "Peptide and Protein Drug Delivery" in <u>Advances in Parenteral Sciences</u> (Vincent H.L. Lee, ed., Marcel Dekker, Inc., 1990) 691-695;											
		Li et al., "Glatiramer Acetate Blocks the Activation of THP-1 Cells by Interferon-γ", <u>Eur. J. Pharmacol.</u> , 1998, 342: 303-310;											
		Lisak, et al., "Effect of Treatment with Copolymer 1 (Cop-1) on the in Vivo and in Vitro Manifestations of Experimental Allergic Encephalomyelitis (EAE)", <u>J. Neurol. Sci.</u> , 1983, 62, 281-293;											
		Matsunaga, et al., "Complementation of Class II A Alleles in the Immune Response to (Glu-Lys-Tyr) Polymers", <u>Yokohama Med. Bull.</u> , 1988, 39(1-2): 9-19 (Abstract);											
		Maurer, et al., "Interpretations of Immune Responses of Mice to Poly(Glu60Lys40), its Modified Derivatives, and the Terpolymers Poly (Glu55Lys37Leu8) and Poly (Glu56Lys37Ser7)", <u>Clin. Immunol. Immunopathol.</u> , 1980, 15(3): 344-356 (Abstract);											
		McDermott, et al., "Antigen-induced Suppression of Experimental Allergic Neuritis in the Guinea Pig", <u>J. Neurol. Sci.</u> , 1980, 46, 137-143;											
		McGavern, et al., "Do Antibodies Stimulate Myelin Repair in Multiple Sclerosis", <u>The Neuroscientist</u> , 1999, 5(1): 19-28;											
		Meiner, "COP-1 Multicenter Clinical Trial in Exacerbating-relapsing Multiple Sclerosis: One Year Follow-up", <u>J. Neurol.</u> , 1991(Suppl. 1) (Abstract);											
		Meiner, et al., "The Israeli COP-1 Multicenter Clinical Trial in Exacerbating-relapsing Multiple Sclerosis - Two-year Follow-up", in <u>9th Congress of the European Committee for Treatment and Research in Multiple Sclerosis</u> , Florence (Italy), October-November, 1993, 48 (Abstract);											
CyW		Mengle-Gaw, "The Major Histocompatibility Complex (MHC)", in <u>Encycl. Molecular Bio.</u> (Oxford Blackwell Science Ltd, 1994) 602-606;											
EXAMINER		Chang						DATE CONSIDERED		01/20/06			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>													

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442				
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure						
					Filing Date: February 10, 2004		Group Art Unit 1614-1649				
U.S. PATENT DOCUMENTS											
Examiner Initial	US	Document Number				Date	Name	Class	Subclass	Filing Date if Appropriate	
Cyw	US	09	7	6	8	8	7	2	01/23/01	Aharoni et al.	
Cyw	US	09	8	1	6	9	8	9	03/23/01	Gad et al.	
Cyw	US	09	8	7	5	4	2	9	06/05/01	Yong et al.	
FOREIGN PATENT DOCUMENTS											
		Document Number				Date	Country	Class	Subclass	Translation	
										Yes No	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
Cyw		Milo, et al., "Inhibition of Myelin Basic Protein-specific Human T-cell Lines by COP-1", <u>Israel J. Med. Sci.</u> , 1992, 28, 486 (Abstract);									
		Milo, et al., "Copolymer-1 (COP-1) Regulates Class II MHC Expression and Cytokine Synthesis in the THP-1 Monocyte-Macrophage Cell Line" in <u>The IBC Conference on Multiple Sclerosis</u> , San Diego (USA), December 10, 1993 (Abstract);									
		Milo, et al., "Additive Effect of Copolymer-1 and Interferon- β on the Immune Response to Myelin Basic Protein", <u>Assaf Harofeh Medical Center, Sackler School of Medicine, Tel-Aviv University of Maryland School of Medicine</u> , 1994, 22;									
		Milo, et al., "Copolymer-1 and Interferon- β Additively Suppress the Immune Response to Myelin Basic Protein by Inhibiting Antigen Presentation", <u>J. Neuroimmunol.</u> , 1994, 54, 183 (Abstract);									
		Milo, et al., "Additive Effects of COP-1 and IFN-Beta on Immune Responses to Myelin Basic Protein", <u>Neurol.</u> , 1994, 44(Suppl. 2), A212;									
		Milo, et al., "Additive Effects of Copolymer-1 and Interferon β -1b on the Immune Response to Myelin Basic Protein", <u>J. Neuroimmunol.</u> , 1995, 61, 185-193;									
		Milo, et al., "Additive Effects of COP-1 and IFN-Beta on Immune Responses to Myelin Basic Protein", <u>Neurol.</u> , 1994, 44(Suppl. 2), A212;									
		Myers, et al., "The Peculiar Difficulties of Therapeutic Trials for Multiple Sclerosis", <u>Neurologic Clinics</u> , 1990, 8(1), 119-141;									
		Nightingale, et al., "Access to Investigational Drugs for Treatment Purposes", <u>Am. Family Physician</u> , 1994, 50(4), 845-847;									
		O'Connor, et al., "Powders" in <u>The Science and Practice of Pharmacy</u> , Remington, 1995, 2, 1598-1614 Pender et al. <u>Int. Med. Journal</u> , 2002, 32: 554-563;									
Cyw		Porter, "Coating of Pharmaceutical Dosage Forms," in <u>The Science and Practice of Pharmacy</u> , Remington, 1995, 2, 1650-1659									
EXAMINER		Chang				DATE CONSIDERED 1/20/06					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure			
					Filing Date: February 10, 2004		Group Art Unit 1614 1649	
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
Cyr		Prat, et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy," <u>Ann. Neurol.</u> , 1999, 46: 253-256;						
		Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", <u>J. Neuroimmunol.</u> , 1992, 37, 75-84;						
		Reilly, Jr., W.J., "Pharmaceutical Necessities" in <u>The Science and Practice of Pharmacy</u> , Remington, 1995, 2, 1380-1416;						
		Rodriguez, <u>Neurological Therapeutics</u> , 1998, 15(3): 245-250;						
		Rolak, "Copolymer-I Therapy for Multiple Sclerosis", <u>Clin. Neuropharmacology</u> , 1987, 10(5), 389-396;						
		Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", <u>Blood</u> , 1994, 84(8), 2802-2810;						
		Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in <u>Am. Soc. Hematology</u> , 37 th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract);						
		Schwartz, et al., "Gene Complementation in the T Lymphocyte Proliferative Response to Poly (Glu57Lys38Tyr5): Evidence for Effects of Polymer Handling and Gene Dosage", <u>J. Immunol.</u> , 1979, 123(1): 272-278 (Abstract);						
		Sela, et al., "Experimental Allergic Encephalomyelitis" in <u>Menarini Series on Immunopathology</u> , vol. 1, <u>First Symposium of Organ Specific Autoimmunity</u> , Cremona, Italy, June, 1977, (Miescher P.A. ed., Schwabe Co., Basel, 1978), 9-21;						
Cyr		Sela, "Polymeric Drugs as Immunomodulatory Vaccines Against Multiple Sclerosis", <u>Makromol. Chem. Macromol. Symp.</u> , 1993, 70/71, 147-155;						
EXAMINER		DATE CONSIDERED						
Changm Sang		12/0/06						
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant</p>								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure			
					Filing Date: February 10, 2004		Group Art Unit 1614 1649	
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
C/W		Starzl, Transplantation Proceedings, 1990, 22 (1, Suppl. 1), 5;						
		Sykes, "Immunobiology of Transplantation", <u>Faseb J.</u> , 1996, 10, 721-730;						
		Tarcic, et al., "Copolymer 1 (Copaxone) from an Idea to a Drug for Treatment of Multiple Sclerosis" Database HCAPLUS on STN, Israel: AN 1997:333270. Kim, Handasa Kim, 1997, 281(14), 16-18 (Abstract);						
		Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide", <u>Israel J. Med. Sci.</u> , 1971, 7, 630-631 (Abstract);						
		Teitelbaum, et al., "Protection Against Experimental Allergic Encephalomyelitis", <u>Nature</u> , 1972, 240, 564-566;						
		Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer", <u>Clin. Immunol. Immunopath.</u> , 1974, 3, 256-262;						
		Teitelbaum, et al., "Dose-response Studies on Experimental Allergic Encephalomyelitis Suppression by COP-1", <u>Israel J. Med. Sci.</u> , 1974, 10(9), 1172-1173;						
		Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Baboons by Cop 1", <u>Israel J. Med. Sci.</u> , 1977, 13, 1038 (Abstract);						
		Teitelbaum, et al., "Blocking of Sensitization to Encephalitogenic Basic Protein in Vitro by Synthetic Basic Copolymer (COP 1)" in <u>Cell Biology and Immunology of Leukocyte Function</u> (Academic Press, New York, 1979) 681-685;						
		Teitelbaum, "Suppression of Experimental Allergic Encephalomyelitis with a Synthetic Copolymer - Relevance to Multiple Sclerosis", in <u>Humoral Immunity in Neurological Diseases</u> (Karcher D., Lowenthal A. & Strosberg A.D., eds., Plenum Publishing Corp., 1979) 609-613;						
		Teitelbaum, et al., "Monoclonal Antibodies to Myelin Basic Protein Cross React with Synthetic EAE-suppressive Copolymer, COP 1" in <u>Proc. 7th Eur. Immunol. Mtg.</u> , Jerusalem, September 8-13, 1985 (Abstract);						
C/W		Teitelbaum, et al., "Specific Inhibition of the T-cell Response to Myelin Basic Protein by the Synthetic Copolymer Cop 1", <u>Proc. Natl. Acad. Sci. USA</u> , 1988, 85, 9724-9728;						
EXAMINER <i>Chang W. J.</i>		DATE CONSIDERED 1/20/06						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure			
					Filing Date: February 10, 2004		Group Art Unit 1614 1649	
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
Cyr		Teitelbaum, et al., "Clinical Trial of Copolymer 1 in Multiple Sclerosis" <u>J. Israel Med. Assoc.</u> , 1989, CXVI(9), 453-456;						
		Teitelbaum, et al., "Synthetic Copolymer 1 Inhibits Human T-cell Lines Specific for Myelin Basic Protein", <u>Proc. Natl. Acad. Sci. (USA)</u> , 1992, 89, 137-141;						
		Teitelbaum, et al., "Immunological Parameters in a Multicenter Clinical Trial of COP1 in Multiple Sclerosis (MS): A 2-year Follow-up", <u>Neurol.</u> , 1994, 44(Suppl. 2), A358;						
		Teitelbaum, et al., "Copolymer 1 from the Laboratory to FDA", <u>Israel J. Med. Sci.</u> , 1997, 33, 280-284;						
Cyr		The COP-1 Multicenter Clinical and Research Group Study, "COP-1 Multicenter Trial in Relapsing Remitting Multiple Sclerosis: 3 Year Follow Up", <u>Abstracts of Symposia and Free Communication</u> , Barcelona (Spain), June 25-29, 1994, 241 (Suppl. 1), 6;						
		Thompson, "MCQ Tutor: Medical Immunology Multiple Choice Questions", <u>Immunol. Today</u> , 1985, 6(4), 141;						
		Tisch, et al., "Antigen-specific immunotherapy: Is it a Real Possibility to Combat T-Cell-Mediated autoimmunity?" <u>Proc. Natl. Acad. Sci. U.S.A.</u> , 1994, 91, 437-438;						
		Trannoy, et al., "Epitope-specific Regulation of the T Cell Repertoire: Carrier Recognition in Association with I-E or I-A Does Not Influence the Restriction of Hapten-Specific T Cells", <u>Eur. J. Immunol.</u> , 1985, 15(12): 1215-1221 (Abstract);						
		Van den Bogaerde, et al., "Induction of Long-Term Survival of Hamster Heart Xenografts in Rats", <u>Transplantation</u> , 1991, 52, 15-20;						
		Van Noort, et al., <u>International Review of Cytology</u> , 1995, 178: 127-205;						
		Warrington, et al., "Human Monoclonal Antibodies Reactive to Oligodendrocytes Promote Remyelination in a Model of Multiple Sclerosis", <u>Neurobiology</u> , 2000, 97(12): 6820-6825;						
		Warrington, et al., "Immunoglobulin-Mediated CNS Repair", <u>J. Allergy Clin. Immunol.</u> , 2001, S121-S125;						
Cyr		Webb, et al., "Further Studies on the Suppression of Experimental Allergic Encephalomyelitis by Synthetic Copolymer", <u>Israel J. Med. Sci.</u> , 1972, 8, 656-657.						
EXAMINER		DATE CONSIDERED						
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant</p>								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60726-AZ		U.S. Serial No. 10/776,442	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant: Moses Rodriguez and Daren Ure			
					Filing Date: February 10, 2004		Group Art Unit 1614 1649	
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
C/W		Webb, et al., "Molecular Requirements Involved in Suppression of EAE by Synthetic Basic Copolymers of Amino Acids", <u>Immunochem.</u> , 1976, 13, 333-337;						
		Webster's II New Riverside University Dictionary, The Riverside Publishing Company, 1984, 933;						
		Weinshenker, et al., "Natural History and Treatment of Multiple Sclerosis", <u>Current Opinion in Neurol. and Neurosurgery</u> , 1992, 5, 203-211;						
		Wender, "Copolymer 1 (COP-1) in the Treatment of Multiple Sclerosis (letter)" <u>Neur. Neurochir. Pol.</u> , 1990, 24, 113;						
		Winer, "COP 1 Therapy for Multiple Sclerosis", <u>New Eng. J. Med.</u> , 1987, 317(7), 442-444;						
		Zisman, et al., "Direct Binding of a Synthetic Multichain Polypeptide to Class II Major Histocompatibility Complex Molecules on Antigen-presenting Cells and Stimulation of a Specific T-cell Line Require Processing of the Polypeptide", <u>Proc. Natl. Acad. Sci. USA</u> , 1991, 88(21): 9732-9742 (Abstract);						
C/W		Zisman, et al., "Dichotomy Between the T and the B Cell Epitopes of the Synthetic Polypeptide (T,G)-A-L", <u>Eur. J. Immunol.</u> , 1994, 24(10): 2497-2505 (Abstract);						
EXAMINER		Chang in 54			DATE CONSIDERED 1/20/06			
<p>•EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant</p>								

Group Art Unit
~~1614~~ 1649

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

[illegible][illegible]

DATE CONSIDERED 1/20/06

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Moses Rodriguez et al.
Serial No.: 10/776, 442
Filed: February 10, 2004
Exhibit A